Introduction
Since a novel coronavirus has caused worldwide outbreak of COVID-19. The
spectrum of COVID-19 ranges from mild to severe and even
death1-4. Up to now, more than 80% of the confirmed
cases of COVID-19 are mild or common illness. Currently there are no
specific antiviral treatment for COVID-195-7. The
World Health Organization (WHO) has now declared the coronavirus a
global pandemic.
Since the SARS-CoV-2 is highly infectious, in order to control the
spread of the epidemic, Fangcang hospitals were established as a new
major public health facility, which had large space, multiple beds and
possessed multiple functions, including emergency treatment, clinical
examination and centralized management8-10. Until
Feb.24th, 2020, there have been 16 Fangcang hospitals
established for more than 12,000 patients with mild and common COVID-19
in China. As a requisite functional module of the Fangcang hospital, the
Fangcang pharmacy and clinical pharmacists also played an important role
in ensuring the supply and safety of therapeutic drugs for the COVID-19
patients9.
As the largest Fangcang hospital, Jianghan Fangcang Hospital was the
first one to open up for mild/ moderate COVID-19 patients, which
provided about 1500 beds. Most of the patients had no obvious clinical
symptoms or had mild symptoms after they were hospitalized. Common
respiratory symptoms include fever, dry cough, and shortness of breath.
A few patients were accompanied with nasal obstruction, running nose,
pharyngalgia, myalgia and diarrhea. The therapeutic regimen was simple
and mainly included antiviral and symptomatic treatment. However, the
large number and complicated sources of patients with mental stress and
comorbidities, make the treatment more complicated and difficult. There
were also many special patients, such as child, pregnant and senile ones
resulting in a great difficulty of treatment assignment.
The standard treatment for patients in the Fangcang hospitals included,
as necessary, antiviral agents, traditional Chinese medicines,
immunomodulator, glucocorticoid, intestinal microecological modulators
etc. And other medicines for chronic diseases. Under this circumstance,
there are many drug related problems such as drug interventions, drug
interactions and adverse drug reactions, which lead to high risks of
drug safety in COVID-19 patients, especially for those special patients.
Therefore, it’s important to carry out monitoring of drug therapeutic
effect and adverse reactions, for timely guiding medical workers and
patients to use drugs rationally, provide relevant drug consultation.
This study was a retrospective study on the benefit of pharmaceutical
care for patients in Jianghan Fangcang Hospital. Data were collected
from medical records, patient questionnaire and
WeChat® online service records. After 35 days’
pharmaceutical care, clinical pharmacist help 349 patients solved about
196 different questions concluded in this paper. The satisfaction with
patients was assessed through discharged patients’ questionnaire.